Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment

Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis, inflammatory bowel disease (IBD), and noninfectious uveitis form a distinct group among the immune mediated diseases. Thus, many patients suffer from more than one of these manifestations. Here, we will use term spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) spectrum disease. The aim is to review new targeted pharmacological treatment options for all All biological or synthetic drugs with U.S. Food Drug Administration (FDA) European Medicines Agency (EMA) approval any diagnoses axSpA, PsA, IBD, non-infectious were included. Some have documented efficacy in diseases, e.g. tumor necrosis factor (TNF) inhibitors. However, other are particularly effective specific inflamed tissue approved only two entities, abatacept peripheral vedolizumab This contributes bedside bench understanding immunology underlying this provides clinicians an overview that can assist stratified decisions. We hope help guide speed up spectrum.